MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Portfolio Pulse from
MediWound Ltd. reported its Q4 and full-year 2024 financial results, highlighting a $20 million revenue for 2024 and a projected $24 million for 2025. The company initiated a Phase III trial for EscharEx® and expanded collaborations, including with Kerecis.
March 19, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediWound Ltd. reported $20 million in revenue for 2024 and projects $24 million for 2025. The company initiated a Phase III trial for EscharEx® and expanded strategic collaborations, including with Kerecis.
The financial results show a stable revenue with a positive projection for 2025, which is likely to boost investor confidence. The initiation of a Phase III trial for EscharEx® and expanded collaborations indicate potential growth and innovation, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100